EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis

Jie Zhang, Shihua Lin, Tiantian Zhang, Xing Son, Chaohui Yu

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.111318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Jie Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Ferroptosis, Up-Regulation, Aspartic Acid, Cystathionine beta-Synthase. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Institute of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of non-essential amino acids (NEAAs) contributes to metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Aspartate (ASP), an NEAA serving as a critical precursor for purine, asparagine, and arginine biosynthesis, exhibits unexplored pathophysiological significance in MAFLD. Mass spectrometry profiling identified hepatic ASP as the sole NEAA consistently depleted in both human patients with MAFLD and animal models. Dietary or orally administered ASP supplementation in mice significantly improved insulin sensitivity, suppressed de novo lipogenesis, and enhanced mitochondrial respiration, collectively ameliorating diet-induced MAFLD. Integrative multi-omics analyses revealed that ASP activates the trans-sulfuration pathway through cystathionine β-synthase (CBS) upregulation in hepatocytes, thereby attenuating ferroptosis-evidenced by elevated glutathione and reduced lipid peroxidation. Crucially, pharmacological ferroptosis inhibition (liproxstatin-1) abolished ASP-mediated hepatic improvements, while CBS blockade completely abrogated ASP's therapeutic effects. These findings establish ASP as a novel ferroptosis inhibitor with therapeutic promise for MAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisUp-RegulationAspartic AcidCystathionine beta-SynthaseNon-alcoholic Fatty Liver DiseaseFatty LiverAnimalsMiceHumansMaleMice, Inbred C57BL

Stichwörter der Autor:innen

CBSaspartateferroptosishepatic steatosis

Substanzen

Aspartic AcidCystathionine beta-Synthase

Autor:innen und Institutionen

  • Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: zyyyych@zju.edu.cn.

Förderung

  • Zhejiang Institute of Technology

Zitieren

APA

Zhang, J., Lin, S., Zhang, T., Son, X., & Yu, C. (2026). Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111318

Vancouver

Zhang J, Lin S, Zhang T, Son X, Yu C. Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111318

BibTeX
@article{Zhang2026,
  author = {Zhang, Jie and Lin, Shihua and Zhang, Tiantian and Son, Xing and Yu, Chaohui},
  title = {Aspartate treatment ameliorates metabolic dysfunction-associated fatty liver disease through upregulation of CBS and suppression of ferroptosis},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.111318}
}
Kostenlos starten →